Xbrane Working Towards Q2 2025 US Ranibizumab Approval
Plan Follows April CRL, Addition Of New US Marketing Partner
Xbrane plans to refile its proposed biosimilar to Lucentis by the end of 2024, after the recent disappointment of a US FDA complete response letter. However, the goal requires its manufacturing partners to successfully execute remediation plans.
